Markets ABBV

AbbVie Collaborates With Iambic On AI-Powered Discovery And Development Of Small Molecule Therapies

September 21, 2026 — 08:16 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Monday, AbbVie Inc. (ABBV) announced a multi-year collaboration with Iambic, a clinical-stage life sciences and technology company, to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology.

The collaboration intends to combine Iambic's molecular superintelligence platform featuring purpose-built AI capabilities with the drug-hunting expertise of AbbVie scientists, expecting to design better molecules more efficiently and improve the probability of success.

As per the terms of the deal, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.

In pre-market hours, ABBV was trading at $262.77, down 0.43 percent on the NYSE.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
ABBV

Latest Articles
Data is currently not available